Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|May 6, 2014
Looking Ahead: The Treatment of Colorectal Cancer
Author(s)Marc Peeters, MD, PhD
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, comments on the future of the treatment of patients with colorectal cancer.
Advertisement
Clinical Pearls
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, comments on the future of the treatment of patients with colorectal cancer.
- New drugs must be developed in this space: Patients are living longer and asking for newer options to prolong survival.
- Colorectal cancer is moving towards becoming a chronic disease.
cPatients with colorectal cancer will continue to receive treatment in a multidisciplinary setting: Surgeons, radiation oncologists, and gastroenterologists will be part of the team to personalize treatment strategies.
Advertisement
Related to this article
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5